Transfusional Hemosiderosis Clinical Trial
Official title:
A Multi-Center, Open-label, Non Comparative, Phase II Trial on Efficacy and Safety of ICL670 Given for 1 Year With Dose Adjustments Based on Serum Ferritin in Patients With Chronic Anemia and Transfusional Hemosiderosis Including an Additional 1 Year Extension.
The overall purpose of this trial is to further evaluate the efficacy and safety of deferasirox, dosed initially according to the transfusional iron intake, in patients with transfusion dependant anemia related to disorders other than β-thalassemia and sickle cell disease. During the study, the dose will be adjusted based on serum Ferritin.The overall purpose of the extension is to allow further treatment of patients who have already completed the core study, and to enable collection of long term efficacy and safety data. Patients will continue to receive Deferasirox at the dose they received at the end of the core study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00600938 -
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
|
Phase 2 | |
| Withdrawn |
NCT01927913 -
Treatment of Iron Overload Requiring Chelation Therapy
|
Phase 2 | |
| Completed |
NCT00845871 -
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food
|
Phase 4 | |
| Completed |
NCT01394029 -
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
|
N/A |